QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

Help viewing high resolution images Return to article

Fig. 2. Fak56 protein is not expressed in Fak56^CG1 mutant animals. (A) Immunoblot analysis of wild-type (1) and Fak56^CG1 (2) embryonic lysates using Fak56-specific antibodies, indicates that Fak56 protein is absent in Fak56^CG1 mutant animals. Protein extracts were immunoblotted with anti-Fak56 antibodies (upper panel). Subsequently, the same blot was stripped and reprobed with anti--Tubulin antibodies to ensure equal loading. (B) Wild-type and Fak56^CG1 embryos were analyzed with anti-Fak56 antibodies [(i), (ii), (iv) and (v)], as well as anti-phospho-FAK^Y397 antibodies [(iii) and (vi)]. In wild-type embryos, Fak56 protein is ubiquitously expressed with particularly high levels in the embryonic CNS [(i) and (ii)]. In Fak56^CG1 mutant embryos, Fak56 protein is absent [(iv) and (v)]. Similarly, in wild-type embryos, phosphorylated Fak56 was observed at muscle attachment sites (iii), and was strongly reduced in Fak56^CG1 mutant embryos (vi). (C) Wild-type and Fak56^CG1 embryos were analyzed with anti-myosin heavy chain (MHC) [(i) and (ii)]. No obvious muscle disruption phenotypes were observed in Fak56^CG1 embryos when compared with wild-type. Embryo orientation is anterior to left and dorsal up.

Return to article